As of May 30, 2025
Tema Oncology ETF (NASDAQ: CANC)
Ticker | Name | Share % | |
---|---|---|---|
REGN | Regeneron Pharmaceuticals, Inc. | 4.00% | |
LN | Astrazeneca Plc | 4.26% | |
MRK | Merck & Co Inc - Common | 4.34% | |
JP | Chugai Pharmaceutical Co., Ltd. | 3.84% | |
AS | Argenx Se Spon Adr Each Rep 1 Ord Shs | 4.88% | |
AMGN | Amgen Inc. | 3.39% | |
BPMC | Blueprint Medicines Corp | 3.38% | |
NTLA | Intellia Therapeutics Inc | 3.16% | |
EXEL | Exelixis Inc | 4.29% | |
INCY | Incyte Corp. | 4.49% | |
GILD | Gilead Sciences Inc | 5.51% | |
RVMD | Revolution Medicines Inc Ser C Pc Pp | 5.40% | |
ILMN | Illumina, Inc. | 3.96% | |
CO | Genmab A/s ADR | 4.00% | |
RHHBY | Roche Holdings Ag | 3.92% | |
LLY | Eli Lilly & Co. | 4.55% | |
BBIO | Bridgebio Pharma Inc | 3.89% | |
BMY | Bristol-Myers Squibb Co. | 3.70% | |
BGNE | Beigene, Ltd. Adr | 4.15% | |
FF | Roche Holdings Ag | 5.03% | |
SM | Novartis Ag | 4.32% | |
ZLAB | Zai Lab, Ltd. | 3.85% | |
NUVL | Nuvalent, Inc. | 4.01% | |
SMMT | Summit Therapeutics Plc Spon Adr | 4.09% | |
MRUS | Merus Nv | 3.98% |
The CANC ETF is currently trading at $24.99, which represents a 0.58% change. Over the past 52 weeks, the ETF has traded as high as $30.11 and as low as $20.10.
The expense ratio of CANC is 0.75%. This represents the annual fee that all funds or ETFs charge their shareholders.
The total Assets Under Management (AUM) for CANC is 72.21M. This represents the total market value of the assets managed by the ETF.
CANC follows a Large Cap Blend investment style.
The top holdings of CANC include: REGN (4%), LN (4.26%), MRK (4.34%), JP (3.84%), AS (4.88%). These represent the largest positions in the ETF's portfolio.
The average daily trading volume for CANC is 10.04K shares.